IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
IGM Biosciences, Inc. (IGMS)
Last igm biosciences, inc. earnings: 3/26 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in the development of T cell engaging IgM antibodies for the treatment of autoimmune diseases. The Company’s lead candidates include imvotamab, a CD20 x CD3 bispecific T cell engager being developed in rheumatoid arthritis, systemic lupus erythematosus and myositis, and IGM-2644, a CD38 x CD3 bispecific T cell engag
Show less
Read more
Impact Snapshot
Event Time:
IGMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGMS alerts
High impacting IGM Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IGMS
News
- IGM Biosciences, Inc. (NASDAQ: IGMS) had its price target raised by analysts at Stifel Nicolaus from $25.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
- IGM Biosciences GAAP EPS of -$1.01 misses by $0.19, revenue of $0.52M beats by $0.28M [Seeking Alpha]Seeking Alpha
- IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Medivir AB (OSTO:MVIR) Q3 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... [Yahoo! Finance]Yahoo! Finance
IGMS
Earnings
- 11/8/24 - Miss
IGMS
Sec Filings
- 11/20/24 - Form 4
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- IGMS's page on the SEC website